Table 2.
Primary and secondary hemodynamic outcomes measured by minimally invasive hemodynamic monitoring (Vigileo/FloTrac system) in breast cancer patients receiving paravertebral block: differences between treatment groups in estimated means over the time*
| Hemodynamic outcomes | LS means (SE) |
LS mean difference (95% CI) | P† | |
|---|---|---|---|---|
| LG group (n = 40) | LLG group (n = 40) | |||
|
Primary |
||||
| Overall SVV (%) over 60 minutes |
11.13 (0.19) |
15.47 (0.20) |
4.33 (3.80-4.88) |
<0.001 |
|
Secondary |
||||
| Overall MAP (mmHg) over time |
90.42 (1.63) |
90.01 (1.72) |
-0.41 (-5.18-4.37) |
0.864 |
| Overall HR (bpm) over time |
66.17 (1.24) |
66.75 (1.32) |
0.58 (-3.05-4.21) |
0.750 |
| Overall CO (L/min) over 60 minutes | 4.18 (0.10) | 4.05 (0.11) | -0.13 (-0.43-0.18) | 0.414 |
*Abbreviations: LS – least square; SE – standard error; LG – 0.5% levobupivacaine; LLG – 0.5% levobupivacaine + 2% lidocaine; CI – confidence interval; SVV – stroke volume variation; MAP – mean arterial pressure; HR – heart rate; CO – cardiac output.
†RM-ANOVA.